SG11201906226YA - Methods of treating bacterial infections - Google Patents
Methods of treating bacterial infectionsInfo
- Publication number
- SG11201906226YA SG11201906226YA SG11201906226YA SG11201906226YA SG11201906226YA SG 11201906226Y A SG11201906226Y A SG 11201906226YA SG 11201906226Y A SG11201906226Y A SG 11201906226YA SG 11201906226Y A SG11201906226Y A SG 11201906226YA SG 11201906226Y A SG11201906226Y A SG 11201906226YA
- Authority
- SG
- Singapore
- Prior art keywords
- floor
- san diego
- international
- science park
- medicines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444238P | 2017-01-09 | 2017-01-09 | |
| US201762513936P | 2017-06-01 | 2017-06-01 | |
| PCT/US2018/012839 WO2018129479A1 (en) | 2017-01-09 | 2018-01-08 | Methods of treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906226YA true SG11201906226YA (en) | 2019-08-27 |
Family
ID=62791302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906226YA SG11201906226YA (en) | 2017-01-09 | 2018-01-08 | Methods of treating bacterial infections |
Country Status (21)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020006658A2 (pt) * | 2017-10-03 | 2020-09-24 | Melinta Therapeutics, Inc. | métodos de tratamento de infecções bacterianas |
| WO2022026993A1 (en) * | 2020-07-27 | 2022-02-03 | Northwestern University | Antimicrobial choice algorithm for urinary tract infections |
| WO2024018372A2 (en) * | 2022-07-20 | 2024-01-25 | Sri Sathya Sai Institute Of Higher Learning | A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy |
| WO2024228130A1 (en) * | 2023-05-02 | 2024-11-07 | Cipla Limited | Pharmaceutical combinations and compositions thereof comprising antibacterial agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| EP2603514B1 (en) | 2010-08-10 | 2018-07-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2014186309A1 (en) * | 2013-05-15 | 2014-11-20 | Schaeffler Technologies Gmbh & Co. Kg | Reduced drag clutch plate |
| CN112755039A (zh) * | 2015-04-24 | 2021-05-07 | 莱姆派克斯制药公司 | 治疗细菌感染的方法 |
-
2018
- 2018-01-08 ES ES18735813T patent/ES2979266T3/es active Active
- 2018-01-08 KR KR1020247028886A patent/KR20240133785A/ko not_active Ceased
- 2018-01-08 JP JP2019537269A patent/JP7436206B2/ja active Active
- 2018-01-08 WO PCT/US2018/012839 patent/WO2018129479A1/en not_active Application Discontinuation
- 2018-01-08 NZ NZ755141A patent/NZ755141A/en unknown
- 2018-01-08 PL PL18735813.0T patent/PL3565551T3/pl unknown
- 2018-01-08 BR BR112019014089A patent/BR112019014089A2/pt not_active Application Discontinuation
- 2018-01-08 SG SG11201906226YA patent/SG11201906226YA/en unknown
- 2018-01-08 FI FIEP18735813.0T patent/FI3565551T3/fi active
- 2018-01-08 KR KR1020197023321A patent/KR102768209B1/ko active Active
- 2018-01-08 DK DK18735813.0T patent/DK3565551T3/da active
- 2018-01-08 CA CA3048650A patent/CA3048650A1/en active Pending
- 2018-01-08 CN CN201880006135.5A patent/CN110402139A/zh active Pending
- 2018-01-08 HU HUE18735813A patent/HUE066805T2/hu unknown
- 2018-01-08 PT PT187358130T patent/PT3565551T/pt unknown
- 2018-01-08 US US16/474,487 patent/US20190336475A1/en active Pending
- 2018-01-08 EP EP18735813.0A patent/EP3565551B1/en active Active
- 2018-01-08 AU AU2018205327A patent/AU2018205327B2/en active Active
- 2018-01-08 EP EP23159896.2A patent/EP4212157A1/en active Pending
- 2018-01-08 MX MX2019008281A patent/MX390529B/es unknown
-
2019
- 2019-07-09 CL CL2019001918A patent/CL2019001918A1/es unknown
- 2019-07-09 PH PH12019501606A patent/PH12019501606A1/en unknown
- 2019-07-09 MX MX2022001704A patent/MX2022001704A/es unknown
- 2019-08-06 CO CONC2019/0008575A patent/CO2019008575A2/es unknown
-
2020
- 2020-07-17 CL CL2020001886A patent/CL2020001886A1/es unknown
-
2022
- 2022-11-07 JP JP2022178016A patent/JP2023012538A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110402139A (zh) | 2019-11-01 |
| FI3565551T3 (fi) | 2024-06-18 |
| PT3565551T (pt) | 2024-06-14 |
| PH12019501606A1 (en) | 2020-06-15 |
| JP7436206B2 (ja) | 2024-02-21 |
| KR20190104385A (ko) | 2019-09-09 |
| HUE066805T2 (hu) | 2024-09-28 |
| BR112019014089A2 (pt) | 2020-02-04 |
| MX2022001704A (es) | 2022-03-11 |
| ES2979266T3 (es) | 2024-09-25 |
| CO2019008575A2 (es) | 2019-08-30 |
| KR102768209B1 (ko) | 2025-02-18 |
| CA3048650A1 (en) | 2018-07-12 |
| CL2020001886A1 (es) | 2020-12-18 |
| JP2020504154A (ja) | 2020-02-06 |
| EP3565551A1 (en) | 2019-11-13 |
| EP4212157A1 (en) | 2023-07-19 |
| DK3565551T3 (da) | 2024-06-17 |
| PL3565551T3 (pl) | 2024-09-23 |
| AU2018205327A1 (en) | 2019-07-25 |
| MX390529B (es) | 2025-03-20 |
| US20190336475A1 (en) | 2019-11-07 |
| WO2018129479A1 (en) | 2018-07-12 |
| JP2023012538A (ja) | 2023-01-25 |
| NZ755141A (en) | 2023-01-27 |
| EP3565551A4 (en) | 2020-09-23 |
| CL2019001918A1 (es) | 2020-02-14 |
| AU2018205327B2 (en) | 2023-11-30 |
| MX2019008281A (es) | 2019-12-02 |
| KR20240133785A (ko) | 2024-09-04 |
| EP3565551B1 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201906226YA (en) | Methods of treating bacterial infections | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |